Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Rovina (Attica, Greece), D. Simantiraki (Attica, Greece), N. Grekas (Attica, Greece), P. Papanastasiou (Attica, Greece), A. Athanassiou (Attica, Greece), A. Ginis (Attica, Greece). Adherence to FDC Budesonide/Formoterol treatment and lung function of Greek asthmatic patients–COMPLETE study. 2635

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Lung function and reported dyspnea in Greek COPD patients under treatment with fluticasone/salmeterol FDC via Elpenhaler device with or without cardiovascular comorbidity - AEOLOS study. Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 89s Year: 2004 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Effects of add-on treatment with budesonide/formoterol combination in eosinophilic COPD patients Source: International Congress 2017 – Management of COPD Year: 2017 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Predictive factors for asthma control according to ACQ5 in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS Source: International Congress 2017 – Bronchial asthma management Year: 2017